MA55313A - Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii - Google Patents

Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii

Info

Publication number
MA55313A
MA55313A MA055313A MA55313A MA55313A MA 55313 A MA55313 A MA 55313A MA 055313 A MA055313 A MA 055313A MA 55313 A MA55313 A MA 55313A MA 55313 A MA55313 A MA 55313A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
factor viii
viral dna
dna vectors
expressing factor
Prior art date
Application number
MA055313A
Other languages
English (en)
Inventor
Douglas Anthony Kerr
Debra Klatte
Phillip Samayoa
Nathaniel Silver
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA55313A publication Critical patent/MA55313A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055313A 2019-03-13 2020-03-13 Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii MA55313A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817904P 2019-03-13 2019-03-13
US201962856432P 2019-06-03 2019-06-03

Publications (1)

Publication Number Publication Date
MA55313A true MA55313A (fr) 2022-01-19

Family

ID=72426821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055313A MA55313A (fr) 2019-03-13 2020-03-13 Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii

Country Status (13)

Country Link
US (2) US12338275B2 (fr)
EP (1) EP3938523A4 (fr)
JP (3) JP7795357B2 (fr)
KR (1) KR20210151785A (fr)
CN (1) CN113874513A (fr)
AU (1) AU2020234713A1 (fr)
BR (1) BR112021017853A2 (fr)
CA (1) CA3133255A1 (fr)
IL (1) IL286284A (fr)
MA (1) MA55313A (fr)
MX (1) MX2021011039A (fr)
SG (1) SG11202109850SA (fr)
WO (1) WO2020186207A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
EP3833766A1 (fr) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Molécules d'acide nucléique et leurs utilisations pour une thérapie génique non virale
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
US20220356490A1 (en) * 2020-08-23 2022-11-10 Bioverativ Therapeutics Inc. Baculovirus expression system
WO2023069948A1 (fr) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Compositions d'adn et procédés associés
EP4428237A4 (fr) * 2021-11-02 2026-02-25 Gritgen Therapeutics Ltd Molécule d'acide nucléique isolée et son utilisation
JP2023089774A (ja) * 2021-12-16 2023-06-28 株式会社三洋物産 遊技機
JP2025504404A (ja) * 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
WO2025110984A1 (fr) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions et méthodes pour le traitement de la maladie de wilson
KR20260011950A (ko) 2024-07-17 2026-01-26 이민형 수질 시료 채취 드론

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323957A1 (en) * 2007-11-19 2010-12-23 The Regents Of The University Of California The Office Of The President Novel assay for inhibitors of egfr
NZ596058A (en) * 2009-04-30 2013-08-30 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
EP2500434A1 (fr) 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
WO2013093760A2 (fr) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, procédés et trousses pour la préparation de protéines recombinantes sialylées
WO2013151665A2 (fr) * 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine
WO2014127215A1 (fr) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Gène du facteur viii optimisé
EP3044231B1 (fr) * 2013-09-12 2020-08-05 BioMarin Pharmaceutical Inc. Vecteurs de virus adeno-associes comprentants un gène du facteur viii
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US20190032079A1 (en) * 2015-08-03 2019-01-31 Myodopa Limited Systemic synthesis and regulation of l-dopa
TW202446416A (zh) 2015-09-24 2024-12-01 美商拜奧馬林製藥公司 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
MY189674A (en) 2015-10-28 2022-02-24 Sangamo Therapeutics Inc Liver-specific constructs, factor viii expression cassettes and methods of use thereof
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
MX2018010633A (es) * 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
MX2018012537A (es) 2016-04-15 2019-02-25 Univ Pennsylvania Terapia de genes para tratar hemofilia a.
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
PE20200722A1 (es) 2017-08-01 2020-07-21 Spark Therapeutics Inc Metodos de terapia genica del factor viii (fviii)
NZ762100A (en) * 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
KR20210151785A (ko) 2021-12-14
WO2020186207A3 (fr) 2020-12-17
JP2026002894A (ja) 2026-01-08
JP2022524434A (ja) 2022-05-02
SG11202109850SA (en) 2021-10-28
JP2025073123A (ja) 2025-05-12
EP3938523A4 (fr) 2023-06-21
WO2020186207A8 (fr) 2020-11-12
BR112021017853A2 (pt) 2021-11-30
US20250282848A1 (en) 2025-09-11
US12338275B2 (en) 2025-06-24
EP3938523A2 (fr) 2022-01-19
US20220177545A1 (en) 2022-06-09
CA3133255A1 (fr) 2020-09-17
IL286284A (en) 2021-10-31
AU2020234713A1 (en) 2021-11-04
WO2020186207A2 (fr) 2020-09-17
CN113874513A (zh) 2021-12-31
JP7795357B2 (ja) 2026-01-07
MX2021011039A (es) 2021-12-15

Similar Documents

Publication Publication Date Title
EP3938523A4 (fr) Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii
EP3863605A4 (fr) Vecteurs aav1 et leurs utilisations pour le traitement d'indications otiques
MA49513A (fr) Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines
MA51842A (fr) Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion
MA50096A (fr) Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
EP3890786A4 (fr) Vecteur viral adéno-associé recombiné pour l'insertion de gènes
EP3630975A4 (fr) Arn guides modifiés pour moduler l'activité cas9 et procédés d'utilisation
EP3717505A4 (fr) Protéines de liaison à l'adn modifiées
EP3359671A4 (fr) Vecteurs d'adn, transposons et transposases pour la modification du génome eucaryote
EP3737406A4 (fr) Variants de type iib du récepteur de l'activine et leurs méthodes d'utilisation
EP3801496A4 (fr) Agents actifs et leurs procédés d'utilisation pour le traitement de troubles métaboliques et d'une stéatose hépatique non alcoolique
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP3411056A4 (fr) Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage
MA51915A (fr) Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)
EP3966321A4 (fr) Ligases de protéine spécifiques à l'asx et leurs utilisations
EP3821039A4 (fr) Marqueurs de méthylation de l'adn pour la détection non invasive du cancer et utilisations associées
MA49397A (fr) Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
EP3839070A4 (fr) Marqueur lié à la méthylation de l'adn pour diagnostiquer une tumeur, et son application
EP3877527A4 (fr) Compositions et procédés pour le criblage in vivo d'agents thérapeutiques
EP3934466A4 (fr) Sous-vêtement pour hommes
EP3946354A4 (fr) Protéines hétéromultimères et leurs méthodes d'utilisation
EP3833755A4 (fr) Thérapie génique non perturbatrice pour le traitement d'un mma
EP3720423A4 (fr) Procédés et compositions comprenant des lipides cationiques pour stimuler des gènes d'interféron de type 1
EP4051324A4 (fr) Vecteurs de thérapie génique
MA56397A (fr) Protéines de liaison à l'il1rap